Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypercoagulability in the metabolic syndrome.

Max Nieuwdorp1, Erik S G Stroes, Joost C M Meijers

  • 1Department of Vascular Medicine, AMC, Meibergdreef 9 room F4-159.2, 1100 DD Amsterdam, The Netherlands. m.nieuwdorp@amc.uva.nl

Current Opinion in Pharmacology
|March 23, 2005
PubMed
Summary

Metabolic syndrome increases clotting risk through factors like obesity and insulin resistance, leading to hypercoagulability. Further research is needed to confirm venous thromboembolism risks and intervention effectiveness in these patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of VICTORION-1 PREVENT eligibility with subclinical cardiovascular and inflammatory damage in a European population-based cohort.

American journal of preventive cardiology·2026
Same author

Combined LDL-C, Lp(a), and hsCRP Assessment Predicts ASCVD in the Multiethnic HELIUS Cohort.

Journal of the American College of Cardiology·2026
Same author

Safety of low lipoprotein(a) levels: the FOURIER trial.

European heart journal·2026
Same author

The impact of lipoprotein(a) on coronary atherosclerotic plaque phenotype in primary prevention.

European journal of preventive cardiology·2026
Same author

Reduced postprandial lipid accumulation in circulating monocytes by olezarsen attenuates pro-inflammatory changes in hypertriglyceridemic patients.

European heart journal open·2026
Same author

Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.

Circulation·2026

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Hematology

Background:

  • Metabolic syndrome involves obesity, chronic inflammation, and insulin resistance.
  • It presents a hypercoagulable state with elevated clotting factors and impaired fibrinolysis.
  • Endothelial dysfunction and dyslipidemia contribute to platelet activation and thrombosis risk.

Purpose of the Study:

  • To explore the prothrombotic mechanisms in metabolic syndrome.
  • To assess the current understanding of venous thromboembolism risk in metabolic syndrome patients.
  • To identify potential therapeutic targets for hypercoagulability.

Main Methods:

  • Literature review on coagulation and fibrinolysis in metabolic syndrome.
  • Analysis of existing data on obesity as a risk factor for venous thromboembolism.

Related Experiment Videos

  • Evaluation of dyslipidemia's association with procoagulant changes.

    • Main Results:

    • Metabolic syndrome is linked to increased clotting factors and reduced fibrinolytic activity.
    • Obesity is a modest risk factor for venous thromboembolism, but specific data for metabolic syndrome is limited.
    • Dyslipidemia shows associations with procoagulant changes, suggesting a therapeutic target.

    Conclusions:

    • Current evidence does not warrant routine venous thromboembolism prevention in metabolic syndrome.
    • Dyslipidemia represents a potential target for managing hypercoagulability.
    • Further studies are crucial to understand venous thromboembolism incidence and intervention effects in metabolic syndrome, especially given its rising prevalence.